Merck's Keytruda Gets Lung Cancer Nod In Europe
Executive Summary
The Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending an expanded indication for Merck & Co.’s PD-1 antagonist Keytruda (pembrolizumab).
You may also be interested in...
Merck Poised To Be First To Market With A PD-1 For First-Line Lung Cancer
Merck’s Keytruda improved progression-free survival and overall survival in previously untreated non-small cell lung cancer patients in the highly-anticipated KEYNOTE-024 trial, all but guaranteeing a rapid FDA approval in the indication.
BMS Opdivo To Make Splash in Blood Cancer
New data show that Bristol-Myers Squibb Co.'s Opdivo (nivolumab) has promise in treating Hodgkin's lymphoma reinforcing the notion that checkpoint inhibitors have potential in a broad range of cancers.
Text Mining And Machine Reading: The Answer To Pharma's R&D Data Mountain?
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.